We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$362M
AUM Growth
+$9.59M
Cap. Flow
-$13M
Cap. Flow %
-3.59%
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$1.71M
2
BCAX
Bicara Therapeutics
BCAX
+$1.25M
3
CMPX icon
Compass Therapeutics
CMPX
+$1.09M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$1.02M
5
INGN icon
Inogen
INGN
+$992K

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.17M
2
MRUS
Merus
MRUS
+$2.96M
3
TSVT
2seventy bio
TSVT
+$2.12M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.09M
5
RGLS
Regulus Therapeutics
RGLS
+$1.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDWD icon
51
MediWound
MDWD
$184M
$1.25M 0.34%
64,479
– –
GPCR icon
52
Structure Therapeutics
GPCR
$3.53B
$1.22M 0.34%
59,000
– –
BDTX icon
53
Black Diamond Therapeutics
BDTX
$102M
$1.17M 0.32%
471,000
+331,000
+236% +$638K
LRMR icon
54
Larimar Therapeutics
LRMR
$427M
$1.07M 0.3%
371,434
– –
YARW
55
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$1.05M 0.29%
12,722
– –
GOSS icon
56
Gossamer Bio
GOSS
$88.7M
$1.05M 0.29%
849,921
-57,933
-6% -$63.2K
PVLA
57
Palvella Therapeutics
PVLA
$2.18B
$977K 0.27%
43,348
– –
AUTL
58
Autolus Therapeutics
AUTL
$519M
$970K 0.27%
425,616
-161,051
-27% -$266K
IPSC icon
59
Century Therapeutics
IPSC
$363M
$952K 0.26%
1,704,232
– –
NGNE icon
60
Neurogene
NGNE
$686M
$764K 0.21%
51,096
-404
-0.8% -$6.34K
BNTX icon
61
BioNTech
BNTX
$23.1B
$745K 0.21%
7,000
-3,500
-33% -$354K
PYPD icon
62
PolyPid
PYPD
$85.3M
$734K 0.2%
207,900
-83,373
-29% -$244K
KRRO icon
63
Korro Bio
KRRO
$164M
$721K 0.2%
57,691
+10,605
+23% +$153K
CGEN icon
64
Compugen
CGEN
$225M
$485K 0.13%
272,402
– –
AQST icon
65
Aquestive Therapeutics
AQST
$469M
$470K 0.13%
142,000
– –
BCYC
66
Bicycle Therapeutics
BCYC
$275M
$448K 0.12%
64,492
-16,307
-20% -$130K
ERAS icon
67
Erasca
ERAS
$6.38B
$445K 0.12%
350,000
+10,000
+3% +$13.4K
ACET icon
68
Adicet Bio
ACET
$86.1M
$329K 0.09%
33,750
-3,750
-10% -$39.5K
ADCT icon
69
ADC Therapeutics
ADCT
$140M
$327K 0.09%
122,081
-102,000
-46% -$215K
STRO icon
70
Sutro Biopharma
STRO
$425M
$312K 0.09%
43,708
– –
NKTR icon
71
Nektar Therapeutics
NKTR
$2.46B
$258K 0.07%
+10,000
New +$112K
APRE icon
72
Aprea Therapeutics
APRE
$7.42M
$232K 0.06%
137,174
– –
PHGE icon
73
BiomX
PHGE
$1.97M
$181K 0.05%
21,112
– –
PRCT icon
74
Procept Biorobotics
PRCT
$1.04B
$173K 0.05%
+3,000
New +$170K
IFRX icon
75
InflaRx
IFRX
$262M
$158K 0.04%
200,000
-250,000
-56% -$296K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, DAFNA Capital Management held 86 positions worth $362M, up 2.7% from $353M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

DAFNA Capital Management withdrew a net $13M in Q2 2025, closing 10 positions and reducing 21 holdings. Its most notable exit was 2seventy bio, an estimated $2.12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Compass Therapeutics worth $1.37M.

  • DAFNA Capital Management's largest Q2 2025 buy was Compass Therapeutics: 526,660 shares worth $1.37M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q2 2025, an estimated $1.71M increase.
  • DAFNA Capital Management's biggest Q2 2025 reduction was BioCryst Pharmaceuticals, cutting an estimated $3.17M.
  • DAFNA Capital Management fully exited 2seventy bio in Q2 2025, selling an estimated $2.12M.
  • DAFNA Capital Management's ten largest holdings make up 56% of its $362M portfolio in Q2 2025.
  • DAFNA Capital Management opened 3 new positions and closed 10 in Q2 2025.
  • DAFNA Capital Management's portfolio value rose 2.7% quarter-over-quarter to $362M.

Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.